Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Liabilities and Shareholders Equity (2016 - 2026)

Lexaria Bioscience's Liabilities and Shareholders Equity history spans 12 years, with the latest figure at $6.5 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $6.5 million for Q1 2026, down 25.24% from a year ago — trailing twelve months through Feb 2026 was $23.5 million (down 14.6% YoY), and the annual figure for FY2025 was $4.2 million, down 52.92%.
  • Liabilities and Shareholders Equity for Q1 2026 was $6.5 million at Lexaria Bioscience, up from $6.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $11.4 million in Q1 2022 to a low of $63573.0 in Q1 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $6.1 million (2025), against an average of $5.1 million.
  • The sharpest move saw Liabilities and Shareholders Equity tumbled 99.36% in 2022, then skyrocketed 13549.77% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $75723.0 in 2022, then rose by 0.69% to $76245.0 in 2023, then soared by 12745.14% to $9.8 million in 2024, then plummeted by 38.22% to $6.1 million in 2025, then rose by 7.21% to $6.5 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $6.5 million, $6.1 million, and $4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.